NASDAQ:GLTO
Galecto, Inc. Stock News
$0.630
+0.0052 (+0.83%)
At Close: May 24, 2024
Galecto (GLTO) Enters Oversold Territory
07:52am, Monday, 19'th Apr 2021
Galecto (GLTO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update
08:30am, Monday, 29'th Mar 2021
BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced
Tuesday, March 30, 2021 @ 2pm Eastern Time Tuesday, March 30, 2021 @ 2pm Eastern Time
Tuesday, March 30, 2021 @ 2pm Eastern Time. Tuesday, March 30, 2021 @ 2pm Eastern Time.
Galecto expects to continue dosing patients in the 3 mg arm, whereas the 10 mg arm and combinations with nintedanib or pirfenidone will be discontinued at the recommendation of the DSMB Galecto expect
Galecto to Present at Upcoming Investor Conferences
08:00am, Tuesday, 09'th Feb 2021
BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced Hans Schambye,
Galecto Appoints Anne Prener to its Board of Directors
08:00am, Friday, 08'th Jan 2021
BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced t
Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
04:01pm, Monday, 04'th Jan 2021
BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced th
Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update
08:06am, Friday, 11'th Dec 2020
Successfully completed listing on US Nasdaq and raised over $ 150 million during recent IPO and preceding crossover round
BOSTON and COPENHAGEN, Denmark, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, announce
Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors
04:01pm, Monday, 23'rd Nov 2020
BOSTON and COPENHAGEN, Denmark, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and
U.S. IPO Week Ahead: The IPO Market Takes A Break During The Shortened Holiday Week
12:35pm, Sunday, 22'nd Nov 2020
The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 m
Galecto Announces Pricing of Initial Public Offering
09:10pm, Wednesday, 28'th Oct 2020
BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the biologica
